gous (i.e., both are mutant or normal) or heterozygous (i.e., one is mutant, one is normal) ?the most critical step in correlating the SNP with a disease or drug sensitivity.
To do so, Nanosphere scientists employ a two-step process called
ClearReadTM technology. This method sandwiches a target DNA SNP segment between two oligonucleotide sequences to greatly increase detection specificity and sensitivity. One segment identifies any mutations in the DNA and the probe, a highly sensitive gold nanoparticle, creates a strong signal accurately indicating the presence of a specific target SNP. Proof of principle, reproducibility, and the robust, simple and rapid characteristics of this technology were demonstrated with
unamplified DNA samples representing all possible forms of three genes
implicated in hypercoagulation disorders.
Related :
Nanosphere Inc. Technology
'"/>Source:
Eurekalert
Page: 1 2 Related biology news :1.
Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down2.
Novel antiviral technology inhibits RSV infection in mice3.
Novel Enzyme Shows Potential As An Anti-HIV Target4.
Novel Therapy Tested in Mice Could Chase Away Cat Allergies5.
Discovery Could Lead To Novel Approaches In HIV Treatment6.
Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells7.
Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer8.
Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma9.
Novel live reporting system to track cells10.
Field of beams - Novel system uses polarized light pulses to reveal crop health11.
Novel compounds show promise as safer, more potent insecticides